title: Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.
abstract: The immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccines were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/l. The anti-HBs titres were higher in the group of subjects given 20 micrograms vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10 micrograms of vaccine made by Merck, Sharp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32.0 and 44.7% of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.
authors: Department of Internal Medicine, National Hospital of Norway, Oslo.
authors: E
authors: E
authors: Dahl-Hansen
authors: J C
authors: JC
authors: Siebke
authors: S S
authors: SS
authors: Frøland
authors: M
authors: M
authors: Degré
mesh_terms: D000328:Adult; D005260:Female; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D008875:Middle Aged; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects / Q000276:immunology*
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines